APOE and Hepatic steatosis: Although we anticipated that the SGC707-mediated decrease in the hepatic steatosis extent would be paralleled by a reduction in atherosclerosis susceptibility in our Western-type diet-fed apoE knockout mice, SGC707-treated mice exhibited a similar atherosclerosis burden as compared to solvent control-treated mice6.